068330 — Ilshinbiobase Co Balance Sheet
0.000.00%
- KR₩74bn
- KR₩33bn
- KR₩11bn
- 95
- 47
- 39
- 68
Annual balance sheet for Ilshinbiobase Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | ARS/A | ARS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 20,152 | 25,577 | 27,712 | 33,493 | 37,236 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4,633 | 4,251 | 4,322 | 2,714 | 1,898 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 32,018 | 38,171 | 41,175 | 46,528 | 49,822 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 11,218 | 10,842 | 10,698 | 10,433 | 9,993 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 49,548 | 56,439 | 58,451 | 60,618 | 63,940 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,758 | 5,950 | 4,425 | 3,445 | 3,456 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 5,169 | 6,359 | 4,632 | 3,554 | 3,490 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 44,379 | 50,080 | 53,819 | 57,064 | 60,450 |
| Total Liabilities & Shareholders' Equity | 49,548 | 56,439 | 58,451 | 60,618 | 63,940 |
| Total Common Shares Outstanding |